Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Li, Zidong ^a,b   Chen, Bo ^c   Wu, Yiqing ^a,b   Jin, Feng ^c   Xia, Yongjing ^a,b   Liu, Xiangjun ^a,b  

^a Tsinghua University   (China)

^b TSINGHUA UNIVERSITY   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; BETA ACTIN; BISULFITE; BRCA1 PROTEIN; BRCA2 PROTEIN; MESSENGER RNA; PROTEIN P53; APOPTOSIS REGULATORY PROTEIN; BECN1 PROTEIN, HUMAN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; MEMBRANE PROTEIN; TP53 PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER TISSUE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC CORRELATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; MICROSATELLITE MARKER; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; BIOSYNTHESIS; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DOWN-REGULATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INTRONS; LOSS OF HETEROZYGOSITY; MEMBRANE PROTEINS; MIDDLE AGED; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952272127     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-98     Document Type: Article

References (45)

1. Edinger AL, Thompson CB. Defective autophagy leads to cance. Cancer Cell 2003, 4:422-424. 10.1016/S1535-6108(03)00306-4, 14706333.
2. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721. 10.1126/science.290.5497.1717, 2732363, 11099404.
3. Liang XH, Jaskon S, Seaman M, Brown K, Kempkes B, Hibshoosh H, Levine B. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 1999, 402:672-676. 10.1038/45257, 10604474.
4. Yue Z, Jin S, Yang C, Yang C, Levine B. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci 2003, 100:15077-15082. 10.1073/pnas.2436255100, 299911, 14657337.
5. Liang XH, Kleeman LK, Jiang HH, Gordon G, Goldman JE, Berry G, Herman B, Levine B. Protection against fatal Sindbis virus encephalitis by Beclin, a novel Bcl-2 interacting protein. J Virol 1998, 72:8586-8596. 110269, 9765397.
6. Liang XH, Yu J, Brown K, Levine B. Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res 2001, 61:3443-3449.
7. Furuya D, Tsuji N, Yagihashi A, Watanabe N. Beclin 1 augmented cis-diamminedichloroplatinum induced apoptosis via enhancing caspase-9 activity. Exp Cell Res 2005, 307:26-40. 10.1016/j.yexcr.2005.02.023, 15922724.
8. Daniel F, Legrand A, Pessayre D, Vadrot N, Descatoire V, Bernuau D. Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells. World J Gastroenterol 2006, 12:2895-2900.
9. Aita VM, Liang XH, Murty VV, Pincus DL, Yu WP, Cayanis E, Kalachikov S, Gilliam TC, Levine B. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics 1999, 59:59-65. 10.1006/geno.1999.5851, 10395800.
10. Russell SE, Hickey GI, Lowry WS, White P, Atkinson RJ. Allele loss from chromosome 17 in ovarian cance. Oncogene 1990, 7:2069-2072.
11. Sato T, Saito H, Morita R, Koi S, Lee JH, Nakamura Y. Allelotype of human ovarian cancer. Cancer Res 1991, 51:5118-5122.
12. Futreal PA, Soderkvist P, Marks JR, Iglehart JD, Cochran C, Barrett JC, Wiseman RW. Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphisms. Cancer Res 1992, 52:2624-2627.
13. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995, 55:1002-1005.
14. Miremadi A, Oestergaard MZ, Paul PD, Caldas C. Cancer genetics of epigenetic genes. Hum Mol Genet 2007, 16:28-49.
15. Widschwendter M, Jones PA. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin Cancer Res 2002, 8:17-21.
16. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225-3229.
17. Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ. Use of chromatin immunoprecipitation to clone novel E2F target promoters. Mol Cell Biol 2001, 21:6820-6832. 10.1128/MCB.21.20.6820-6832.2001, 99859, 11564866.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
19. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 1996, 93:9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
20. Roessler M, Rollinger W, Mantovani-Endl L, Roessler M, Rollinger W, Mantovani-Endl L, Hagmann ML, Palme S, Berndt P, Engel AM, Pfeffer M, Karl J, Bodenmüller H, Rüschoff J, Henkel T, Rohr G, Rossol S, Rösch W, Langen H, Zolg W, Tacke M. Identification of PSME3 as a Novel Serum Tumor Marker for Colorectal Cancer by Combining Two-dimensional Polyacrylamide Gel Electrophoresis with a Strictly Mass Spectrometry-based Approach for Data Analysis. Mol Cell Proteomics 2006, 5:2092-2101. 10.1074/mcp.M600118-MCP200, 16893879.
21. Zhang Q, Mashima Y, Noda S, Y I, Kudoh J, Shimizu N, Nishiyama T, Umeda S, Oguchi Y, Tanaka Y, Iwata T. Characterization of AOC2 gene encoding a copper-binding amine oxidase expressed specifically in retina. Gene 2003, 318:45-53. 10.1016/S0378-1119(03)00753-4, 14585497.
22. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP. Molecular pathogenesis of inherited hypertension with hyperkalemia: The Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci USA 2003, 100:680-684. 10.1073/pnas.242735399, 141056, 12515852.
23. Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM. Predicting aberrant CpG island methylation. Proc Natl Acad Sci 2003, 100:12253-12258. 10.1073/pnas.2037852100, 218745, 14519846.
24. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005, 5:223-231. 10.1038/nrc1571, 15719030.
25. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of Loss of Heterozygosity in 399 Premalignant Breast Lesions at 15 Genetic Loci. J Natl Cancer Inst 1998, 90:697-703. 10.1093/jnci/90.9.697, 9586667.
26. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 Gene in Sporadic Breast Cancer. Cancer Res 1997, 57:3347-3350.
27. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu JH, Fackenthal J, Tretiakova M, Das S, Olopade OI. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005, 65:10692-10699. 10.1158/0008-5472.CAN-05-1277, 16322213.
28. Rice JC, Massey-Brown KS, Futscher BW. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998, 17:1807-1812. 10.1038/sj.onc.1202086, 9778046.
29. Mueller CR, Roskelley CD. Regulation of BRCA1 expression and its relationship to sporadic breast cancer. Breast Cancer Res 2002, 5:45-52. 10.1186/bcr557, 154136, 12559046.
30. Coles C, Condie A, Chetty U, Steel M, Evans HJ, Prosser J. P53 mutations in breast cancer. Cancer Res 1992, 52:5291-5298.
31. Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 2001, 61:4092-4097.
32. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, Mcmanus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Easton DF. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145. 10.1093/jnci/90.15.1138, 9701363.
33. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal A. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 1996, 13:238-240. 10.1038/ng0696-238, 8640235.
34. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS. Accumulation of p53 Tumor Suppressor Gene Protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992, 84:845-855. 10.1093/jnci/84.11.845, 1317462.
35. Hedenfalk I, Duggan D, Chen YC, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Kallioniemi OP, Wilfond B, Borg A, Trent J. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344:344-539.
36. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999, 21:236-240. 10.1038/6029, 9988281.
37. Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet 2000, 16:69-74. 10.1016/S0168-9525(99)01930-7, 10652533.
38. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 required for transcriptioncoupled repair of oxidative DNA damage. Science 1998, 281:1009-1012. 10.1126/science.281.5379.1009, 9703501.
39. XL X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 1999, 22:37-43. 10.1038/8743, 10319859.
40. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927-39. 10.1016/j.cell.2005.07.002, 16179260.
41. Liang C, Feng P, Ku B, Dotan I, Canaani D, Oh BH, Jung JU. Autophagic and tumor suppressor activity of a novel Beclin 1-binding protein UVRAG. Nat Cell Biol 2006, 8:688-698. 10.1038/ncb1426, 16799551.
42. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054. 10.1056/NEJMra023075, 14627790.
43. Douglas DB, Akiyama Y, Carraway H, Belinsky SA, Esteller M, Gabrielson E, Weitzman S, Williams T, Herman JG, Baylin SB. Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer. Cancer Res 2004, 64:1611-1620. 10.1158/0008-5472.CAN-0318-2, 14996719.
44. Unoki M, Nakamura Y. Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity. FEBS Lett 2003, 554:67-72. 10.1016/S0014-5793(03)01092-5, 14596916.
45. Cheng CK, Chow WC, Loo TY, Chan TK, Chan V. The cell cycle checkpoint gene Rad9 is a novel Oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 2005, 65:8646-8654. 10.1158/0008-5472.CAN-04-4243, 16204032.